RECRUITING

Linezolid for Syphilis Pilot Study

Conditions

Syphilis Linezolid Treponema pallidum Penicillin Early Syphilis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study aims to evaluate the efficacy of linezolid for the treatment of syphilis.

Official Title

Pilot Study of Linezolid for Early Syphilis Treatment

Quick Facts

Study Start:2023-09-28

Study Completion:2025-03

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05548426

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:16 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* 16 years of age or older * Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment * Able to provide informed consent * For PLHIV: on treatment for HIV-infection and most recent viral load \<200 copies/mL or most recent CD4 T-cell count \>350 cells/mL	* Pregnancy or a positive pregnancy test on the day of enrollment * Participants who receive certain psychotropic medications, e.g., MAO inhibitors, SNRIs, SSRIs * Patients showing signs and symptoms of neurosyphilis * Serofast RPR titer * Recent (\<7 days) or concomitant antimicrobial therapy with azithromycin, doxycycline, ceftriaxone, cefixime, or other beta lactam antibiotics (e.g. amoxicillin) * Linezolid or penicillin allergy

Inclusion Criteria

Exclusion Criteria

* 16 years of age or older
* Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment
* Able to provide informed consent
* For PLHIV: on treatment for HIV-infection and most recent viral load \<200 copies/mL or most recent CD4 T-cell count \>350 cells/mL

* Pregnancy or a positive pregnancy test on the day of enrollment
* Participants who receive certain psychotropic medications, e.g., MAO inhibitors, SNRIs, SSRIs
* Patients showing signs and symptoms of neurosyphilis
* Serofast RPR titer
* Recent (\<7 days) or concomitant antimicrobial therapy with azithromycin, doxycycline, ceftriaxone, cefixime, or other beta lactam antibiotics (e.g. amoxicillin)
* Linezolid or penicillin allergy

Contacts and Locations

Study Contact

Jeffrey D Klausner, MD MPH

CONTACT

(415) 876-8901

jdklausner@med.usc.edu

Principal Investigator

Jeffrey D Klausner, MD MPH

PRINCIPAL_INVESTIGATOR

University of Southern California

Study Locations (Sites)

Howard Brown Health

Chicago, Illinois, 60613

United States

Open Arms HealthCare Center

Jackson, Mississippi, 39216

United States

Collaborators and Investigators

Sponsor: University of Southern California

Jeffrey D Klausner, MD MPH, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-28

Study Completion Date2025-03

Study Record Updates

Study Start Date2023-09-28

Study Completion Date2025-03

Terms related to this study

Keywords Provided by Researchers

Linezolid
Treponema pallidum
Penicillin
Early Syphilis

Additional Relevant MeSH Terms

Syphilis